US biotech Imbria Pharmaceuticals has raised $57.5 million in a series B financing round to fund a new mid-stage trial of its ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s (LSE: AZN) Truqap ...

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

Swiss pharma giant Novartis (NOVN: VX) has announced a planned $23 billion investment over five years in US-based ...

Russell Abberley, vice president and general manager of US biotech giant Amgen’s (Nasdaq: AMGN) UK and Ireland unit, has been ...

Late Thursday, the US Food and Drug Administration revealed it is taking a ground-breaking step to advance public health by ...

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

US biotech Atossa Therapeutics (Nasdaq: ATOS) has entered into a research collaboration with China-backed Nona Biosciences, ...

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and ...

Menarini Biotech, a group company of Italy’s Menarini, has entered into a strategic collaboration with ERBC, a leading ...

US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it ...

Solu Therapeutics, a US biotech developing therapies to eliminate disease-driving cells in cancer, immunology and other ...